arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Intellia Therapeutics, Inc.

NTLA

$11.95 ▲ +0.42 (+3.64%) at close

13 Visible periods

27 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Intellia Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.3B

Dividend Yield —

Revenue Growth 16.9% ↘

Op. Margin None

ROIC -51.9% ↘

FCF / Share $-3.65 →

Trailing P/E —

Price / Book 2.1x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

13-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$67.67M

↑ +16.9% —

Net Income Profit after all expenses

$-412.69M

↑ +20.5% —

Operating Margin Operating profit as % of sales

-235.5%

↑ +4.6% —

FCF / Share Free cash flow per share

$-3.65

↓ -1.8% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 May 6, 2014 10-K ↗
Revenue Growth YoY (%)	16.9% Good ↓ Good Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+112%)	59.6% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+644%)	-30.4% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-480%)	57.7% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+621%)	-43.0% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-638%)	34.5% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+332%)	41.6% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+420%)	16.5% Good Good Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+107%)	—	—	—	—	—
EPS Growth YoY (%)	27.4% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	3.1% Caution ↑ Caution Improving Year-over-year change in earnings per share Optimal: > 10%	12.0% Fair Fair Year-over-year change in earnings per share Optimal: > 10%	-63.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—	—	—
Net Income Growth YoY (%)	20.5% Good ↑ Good Improving Year-over-year change in net income	-7.9% Weak ↑ Weak Improving Year-over-year change in net income	-1.5% Weak ↑ Weak Improving Year-over-year change in net income	-77.0% Weak ↓ Weak Declining Year-over-year change in net income	-99.6% Weak ↓ Weak Declining Year-over-year change in net income	-34.9% Weak ↑ Weak Improving Year-over-year change in net income	-16.6% Weak ↑ Weak Improving Year-over-year change in net income	-26.4% Weak ↑ Weak Improving Year-over-year change in net income	-113.5% Weak Weak Year-over-year change in net income	-155.2% Weak Weak Year-over-year change in net income	—	—	—
FCF Growth YoY (%)	-1.8% Weak ↑ Weak Improving Year-over-year change in free cash flow	22.0% Good ↑ Good Improving Year-over-year change in free cash flow	-2.0% Weak Weak Year-over-year change in free cash flow	-34.3% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—
Revenue CAGR 3Y (%)	9.1% Fair ↑ Fair Improving Compound annual revenue growth over 3 years	20.5% Excellent ↑ Excellent Improving Compound annual revenue growth over 3 years	-14.5% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	6.5% Fair ↓ Fair Declining Compound annual revenue growth over 3 years	2.8% Caution Caution Compound annual revenue growth over 3 years	30.5% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—	—	—	—
Revenue CAGR 5Y (%)	3.1% Caution ↓ Caution Declining Compound annual revenue growth over 5 years	6.1% Fair ↓ Fair Declining Compound annual revenue growth over 5 years	3.6% Caution Caution Compound annual revenue growth over 5 years	14.8% Excellent Excellent Compound annual revenue growth over 5 years	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 May 6, 2014 10-K ↗
Operating Margin (%) (%)	—	—	—	—	—	-235.5% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1670%)	-246.8% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1745%)	-298.6% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2091%)	-266.3% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1875%)	—	—	—	—
Effective Tax Rate (%) (%)	—	—	—	—	—	—	—	—	—	—	7.5% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—
Profit Margin (%) (%)	—	—	—	—	—	-231.5% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2029%)	-230.9% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2024%)	-280.4% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2437%)	-258.6% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2255%)	—	—	—	—
FCF Margin (%) (%)	—	—	—	—	—	-92.2% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-255.3% Weak → Weak Stable Free cash flow as a percentage of revenue Optimal: > 10%	-222.2% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-288.6% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—
FCF / Net Income (x)	0.96x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.68x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.85x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.73x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.40x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.11x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.79x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	1.12x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 May 6, 2014 10-K ↗
Return on Invested Capital (%)	-51.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-48.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-38.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-29.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-20.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-20.5% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-31.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-25.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-18.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-12.1% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	58.5% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	-52.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-44.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-39.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-30.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-20.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-20.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-31.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-26.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-18.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-10.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	-16.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-61.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-510%)	-59.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-497%)	-45.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-405%)	-38.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-356%)	-25.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-272%)	-25.5% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-270%)	-36.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-346%)	-30.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-305%)	-22.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-250%)	-15.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-201%)	58.5% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+290%)	—	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 May 6, 2014 10-K ↗
Net Debt (USD)	$-155.46M	$-189.18M	$-226.75M	$-523.51M	$-123.41M	$-160.02M	$-57.23M	$-58.86M	$-340.68M	$-273.06M	$-75.82M	$-9.85M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 May 6, 2014 10-K ↗
Revenue per Share (USD)	$0.62	$0.59	$0.41	$0.68	$0.47	—	—	—	—	—	—	—	—
Basic EPS, GAAP (USD)	$-3.81	$-5.25	$-5.42	$-6.16	$-3.78	—	—	—	—	—	—	—	—
Free Cash Flow per Share (USD)	$-3.65	$-3.59	$-4.60	$-4.51	$-3.35	—	—	—	—	—	—	—	—
Book Value per Share (USD)	$5.77	$8.55	$11.29	$14.19	$13.97	$7.96	$5.38	$6.15	$7.09	$5.83	$-8.29	—	—
Tangible Book Value per Share (USD)	$5.77	$8.55	$11.29	$14.19	$13.97	$7.96	$5.38	$6.15	$7.09	$5.83	$-8.29	—	—
Basic Weighted Avg Shares (shares)	108.38M	98.85M	88.77M	76.97M	70.89M	—	—	—	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 May 6, 2014 10-K ↗
Working Capital (USD)	$423.83M	$529.01M	$883.12M	$1.09B	$643.47M	$552.26M	$253.85M	$284.40M	$323.47M	$250.58M	$66.93M	—	—
Total Equity (USD)	$671.39M	$871.96M	$1.05B	$1.24B	$1.04B	$527.07M	$269.88M	$277.92M	$300.60M	$209.84M	$-21.20M	$7.57M	$0.00

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 May 6, 2014 10-K ↗
Sales/Revenue/Turnover (USD)	$67.67M	$57.88M	$36.27M	$52.12M	$33.05M	$57.99M	$43.10M	$30.43M	$26.12M	—	—	—	—
Depreciation Expense (USD)	$9.77M	$10.29M	$8.98M	$7.57M	$6.89M	$6.31M	$5.59M	$4.46M	$2.99M	$1.10M	$328.00K	—	—
Net Income, GAAP (USD)	$-412.69M	$-519.02M	$-481.19M	$-474.19M	$-267.89M	$-134.23M	$-99.53M	$-85.34M	$-67.54M	$-31.63M	$-12.40M	—	—
Operating Cash Flow (USD)	$-394.74M	$-348.88M	$-394.09M	$-333.29M	$-225.03M	$-49.91M	$-103.24M	$-61.26M	$-65.28M	—	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 13 years · 47 quarters

Intellia Therapeutics, Inc.

Analytical Summary

13-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare NTLA with peers